Revolution Medicines, Inc. - Common Stock (NQ:RVMD)

193.95 +4.19 (+2.21%)

Delayed Quote Updated: 4:00 PM EDT, Oct 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Revolution Medicines, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines? ↗

September 24, 2026

Revolution Medicines' stock is up 330% in a year on drug development progress; you may want to spread your bets with Royalty Pharma instead.

Via The Motley Fool

Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 18, 2026

Axsome is generating revenue from approved drugs but missing estimates and widening losses. Revolution Medicines just changed the standard of care for one of the deadliest cancers in existence.

Via The Motley Fool

Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy? ↗

September 17, 2026

This company has succeeded where many others have failed.

Via The Motley Fool

Revolution Medicines (NASDAQ:RVMD) Misses Q2 Estimates, Yet FDA Accepts Daraxonrasib Application ↗

August 05, 2026

Via Chartmill

Revolution Medicines (NASDAQ:RVMD) Flashes Strong Technical Breakout Setup ↗

July 30, 2026

Via Chartmill

MarketBeat Week in Review – 09/07 - 09/11 ↗

September 12, 2026

Stocks fell this week on oil prices and Fed rate-hike expectations, though Oracle's earnings underscored AI infrastructure strength. MarketBeat analysts recap top stories on earnings, defense, AI, and...

Via MarketBeat

Topics Artificial Intelligence Economy

Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 11, 2026

Amgen is profitable and paying a growing dividend, while Revolution Medicines is burning cash to fund what could be one of the most important cancer drug launches in years.

Via The Motley Fool

Revolution Medicines Got Its Breakthrough—What Moves It Next? ↗

September 04, 2026

FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.

Via MarketBeat

$100 Invested In Revolution Medicines 5 Years Ago Would Be Worth This Much Today ↗

September 04, 2026

Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 35.53% on an annualized basis producing an average annual return of 46.85%. Currently, Revolution Medicines has a...

Via Benzinga

Revolution Medicines Wins FDA Approval for RASONQUE in Metastatic Pancreatic Cancer ↗

August 28, 2026

Revolution Medicines (NASDAQ:RVMD) said the U.S. Food and Drug Administration has approved daraxonrasib under the brand name RASONQUE for certain adults with metastatic pancreatic adenocarcinoma. The...

Via MarketBeat

Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X? ↗

August 28, 2026

The biotech's Rasonque is already available for prescription.

Via The Motley Fool

Here's How Much $1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth Today ↗

August 26, 2026

Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 38.1% on an annualized basis producing an average annual return of 49.25%. Currently, Revolution Medicines has a...

Via Benzinga

Billionaire Stanley Druckenmiller Continues to Load Up on Revolution Medicines. Does He Know Something Wall Street Doesn't? ↗

August 25, 2026

One of the most successful investors ever really likes this up-and-coming biotech stock.

Via The Motley Fool

GLP-1 Drugs Are Huge. These 2 Stocks Are Tapping Into an Even Bigger Opportunity ↗

August 24, 2026

Could these 2 stocks outperform most GLP-1-focused companies over the medium term?

Via The Motley Fool

Meet the Vanguard ETF That's Crushing the S&P 500 and Nasdaq-100 Despite Not Owning Micron, Sandisk, or Any of the "Magnificent Seven" Stocks ↗

August 18, 2026

Small-cap stocks are finally recovering after years of underperforming the major indexes.

Via The Motley Fool

Topics Artificial Intelligence ETFs Stocks

Revolution Medicines (RVMD) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

Biotech advances RAS-inhibitor pipeline with $3.9B cash and FDA acceptance of daraxonrasib NDA.

Via The Motley Fool

Topics Earnings

Here’s How Much You Would Have Made Owning Revolution Medicines Stock In The Last 5 Years ↗

August 07, 2026

Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 38.08% on an annualized basis producing an average annual return of 49.88%. Currently, Revolution Medicines has a...

Via Benzinga

Revolution Medicines Q2 Earnings Call Highlights ↗

August 06, 2026

Revolution Medicines (NASDAQ:RVMD) said its second-quarter 2026 results reflected continued investment in late-stage cancer programs, commercial launch preparations and manufacturing capacity as it...

Via MarketBeat

Topics Earnings

Billionaire Stanley Druckenmiller Bought This Biotech Stock That Has Surged 400%. Is It Still a Buy? ↗

August 03, 2026

This billionaire investor is betting big on a revolutionary approach in treating pancreatic cancer.

Via The Motley Fool

Why Billionaire Stanley Druckenmiller and Wall Street Analysts Love This Biotech Stock ↗

August 02, 2026

The company is on the verge of becoming a commercial-stage biotech, with two promising therapies in phase 3 trials.

Via The Motley Fool

Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now ↗

July 29, 2026

But is that performance sustainable?

Via The Motley Fool

This Stock Has Skyrocketed 125% in 2026 -- and Billionaire Stanley Druckenmiller Is Loading Up on It ↗

July 17, 2026

Revolution Medicines could be a revolutionary biotech stock.

Via The Motley Fool

Better Growth Buy: Axsome vs Revolution Medicines ↗

July 09, 2026

These stocks both scored a win in the first half of the year.

Via The Motley Fool

Topics Artificial Intelligence

European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process

July 07, 2026

From Revolution Medicines, Inc.

Via GlobeNewswire

These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More ↗

July 06, 2026

These stocks have jumped in the double- and triple-digits.

Via The Motley Fool

Topics Artificial Intelligence Economy Stocks

Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy? ↗

July 05, 2026

The company recently wowed investors with clinical trial results.

Via The Motley Fool

Revolution Medicines Has a $40 Billion Market Cap and Generates No Revenue. Here's Why That's Not Absurd. ↗

July 01, 2026

This pre-commercial biotech is worth more than some drugmakers that generate consistent sales.

Via The Motley Fool

Can Revolution Medicines Be a Game-Changer Stock? ↗

June 11, 2026

This company's potential pancreatic cancer blockbuster could be a watershed moment.

Via The Motley Fool

Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock. ↗

June 05, 2026

Can the drugmaker justify its valuation?

Via The Motley Fool

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

June 03, 2026

Via Investor Brand Network

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.